Introdução: Valores elevados de lipoproteína(a), relacionados com a progressão da aterosclerose, são frequentemente considerados marcadores de trombose. O perfil de lipoproteína(a) foi avaliado num grupo de doentes sem eventos cardiovasculares mas com elevado risco vascular, estabelecendo-se a correlação com outros fatores de risco cardiovascular e inferindo-se os resultados para doentes com alterações metabólicas e, pelo menos, dois fatores de risco vascular. 
INTRODUCTION
Atherosclerosis remains the major cause of death and premature disability in developed societies. 1 Current predictions estimate that by 2020 cardiovascular diseases (CVD), 2 particularly atherosclerosis, will become a global leading cause of death. 3 Lipoprotein(a), or Lp(a), is identical to the low-density lipoprotein cholesterol (LDLc), with the addition of apolipoprotein A (apoA), a highly glycosylated protein. 4, 5 Lp(a) is often considered a marker of thrombosis, similarly to plasminogen, and a risk factor for CVD. 6 The cholesterol present in LDLc accounts for more than half of plasma cholesterol, in most individuals. Approximately 70% of the circulating LDLc is cleared by LDL-receptor-mediated endocytosis in the liver. ApoA is synthesized in the liver and attached by disulphide linkage to apoB-100, a structural protein of Lp(a). Also, apoB is the main structural protein of chylomicrons. 2 The human liver produces apoB-100, whereas the intestine produces apoB-48. Clearance of Lp(a) occurs mainly through the liver, but the uptake pathway is still unknown. 7 Nevertheless, Lp(a) is recognized as a strong risk factor for aortic and mitral stenosis in peripheral artery disease and might present other functions, including an important role in the association between atherosclerosis and thrombosis. 8, 9 Portugal is a Southern European country where CVD are the first cause of mortality and stroke incidence is higher compared to other European countries. 10 In this context, we assessed the levels of Lp(a) in Portuguese patients, who regularly attended outpatient consultations at the clinic of metabolism and vascular risk, over a two-year period. In addition, those patients had metabolic disorders and, at least, two cardiovascular risk factors (CVRF), but no previous cardiovascular events. Thus, the aim of this study is to determine the mean values of Lp(a) in the sample of patients and to infer the use of Lp(a) as an indicator of vascular risk in the Portuguese population with metabolic disorders and, at least, two CVRF.
MATERIAL AND METHODS
The longitudinal observational study included 516 patients, as a random sample of a universe of 1677 patients from an outpatient setting at a clinic of metabolism and vascular risk. Inclusion criteria were defined for those patients without cardiovascular events having, at least, two family or personal CVRF and attending an outpatient consultation about metabolism and vascular risk for primary prevention, for at least two years (between 1995 and 2015), on a quarterly periodicity. All patients accepted and signed the informed consent form. The protocol used in this study was approved by the local Ethics Committee of the São João Hospital Center. All procedures conducted in this study comply with the Declaration of Helsinki.
Patients were assessed for sociodemographic data, including their professional status, in accordance with the 2010 classification, by the Portuguese National Statistics Institute (Instituto Nacional de Estatística, INE). Afterwards, clinical characterization of the study participants was determined, at baseline, by anthropometric, biochemical and cardiovascular evaluation. The following tests were conducted: electrocardiogram (ECG), two-dimensional echocardiogram with ejection fraction calculation, and doppler ultrasonography of the supra-aortic trunks with evaluation of the carotid intima-media thickness (IMT). In addition, liver morphological changes were evaluated by ultrasonography. For classification of alcohol consumption, the following criteria were used: never; moderate, if one or two drinks daily; excessive, if three drinks daily; alcoholism; and abstinence, if at least a year had passed since the last drink. Evaluation of vascular risk was performed considering the three most used scores: Framingham risk score (FRS), atherosclerotic cardiovascular disease (ASCVD) -AHA/ACC, 11 and systematic coronary risk evaluation (SCORE)-ESC. 7 Results were summarized as mean, median and standard deviation or count and percentage, for characterization of the study population. Normality distribution of data was assessed by the usual methodology used for validation (i.e., Kolmogorov-Smirnov test and Shapiro-Wilk test). For quantitative comparison of two independent groups, we used the t-test for independent samples or the Mann-Whitney nonparametric test, depending on the assumptions' validation by the statistical test. Spearman's correlation coefficient (SCC) was used to assess the relationship between two quantitative variables, in case the normality assumption was not verified. Regarding the sample distribution by age groups, we used the Kruskal-Wallis (KW) non-parametric test, instead of ANOVA F-test, whenever the distributions within groups presented relevant deviations from normality. The KW test allowed a comparative analysis between three or more independent groups and a quantitative or ordinal variable (as the dependent variable). Bonferroni correction for multiplicity of testing was used to verify age groups contrast [α' = 0.005, for α (0.05)/k (10 tests)]. All statistical tests were 2-tailed considering a significance level of 5%. The statistical analysis was conducted using the software IBM ® SPSS ® Statistics 19.
RESULTS

Sociodemographic parameters at first consultation
Most of the patients were women (56.6%) and Caucasian (98.6%). The patients' median age was 46 years. Regarding the educational background, 76.6% of the patients did not complete the third cycle; of those, 60.5% completed only the first cycle. Concerning the professional status, 72.5% of the patients were active and 13.2% were retired but still working. Among those actively employed patients, 40.5% had elementary occupations, 17.6% were skilled industrial, construction or craft workers and 17.4% were personal, protection or security service workers or sales workers.
Anthropometric and clinical evaluation
The median weight was 75.3 kg (range: 7.75 -125.6 kg), while the median body mass index (BMI), calculated in kilogram per square meters, was 28.57 (range, 16.53 -47.63 kg/m²). Amongst the study population, 25.0% had normal weight and 36.0% excess weight (BMI, 25 -29 kg/ m²). Moreover, 26.2% of patients had grade I obesity (BMI 30 -34 kg/m²), 9.9% grade II obesity (BMI 5 -39 kg/m²), 2.5% grade III obesity (BMI 40 -44 kg/m²) and 0.4% morbid obesity (BMI ≥ 45 kg/m²). The abdominal (waist-to-hip) circumference (AC) had a median of 94 cm (range: 44 -138 cm) and the average triceps skinfold (TSF) was 2.51 ± 1.13 cm (range: 0.3 -5.0 cm; median: 2.4 cm).
Regarding cardiovascular evaluation, the average systolic blood pressure (SBP) was 145.52 ± 30.29 mmHg (range: 78 -300 mmHg) with a median of 144 mmHg. The average diastolic blood pressure (DBP) was 87.91 mmHg (range: 42 -148 mmHg) with a median of 90 mmHg. In addition, the average heart rate was 88.98 ± 11.79 bpm (range, 50 -170 bpm) with a median of 90 bpm. Overall, 50.6% of patients had normal cardiac auscultation. 12 Concerning the lifestyle and patients' habits, 66.0% had a moderate alcohol consumption, ranging from one (20.8%) to two daily drinks (45.2%), whereas 15.5% showed an excessive alcohol consumption. Alcoholism was diagnosed in Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com 7.0% of patients and abstinence in 0.4%. Moreover, 71.9% did not practice regular physical activity, while 75.4% were non-smokers, 11.6% were ex-smokers and 13.0% were smokers. In terms of the liver morphological evaluation, changes were detected through ultrasound in 509 patients (98.6%). Briefly, a pattern of hepatic steatosis was found in 435 patients (85.4%), of which 208 (40.8%) had associated hepatomegaly. Only 5.6% of patients presented changes in liver function tests.
Vascular risk calculations
The 10-year vascular risk was estimated based on the most commonly used vascular risk scores. Thus, both ASCVD and FRS scores revealed a high median value for the estimated vascular risk, at 10 years, whereas the SCORE low-risk algorithm indicated a moderated median value.
Laboratory values
Laboratory parameters assessed at the first consultation are described in Table 1 . Briefly, a relevant increase of Creactive protein (CRP), fibrinogen, homocysteine and Lp(a) were observed. HDLc showed a median value of 29.00 mg/ dl (min: 11.00 mg/dL), while a median value of 172.00 mg/dL (max: 299 mg/dl) was obtained for LDLc. The average CRP was 1.15 ± 1.01 (min-max: 0.5 -9.7 mg/dL), with a median value of 0.80 mg/dl. An average value of 7.14 ± 2.80 (minmax: 2.1 -16 mg/dL) was found for uric acid. Urinary albumin excretion (UAE) showed a median rate of 15.80 mcg/ min/24 h (min-max: 0.5 -459 mcg/min/24h). Furthermore, the median value for homocysteine was 21.00 mmol/L (minmax: 7.0 -44.0 mmol/L) and the average Lp(a) was 62.57 ± 21.64 (min-max: 9.9 -110 mg/dL), with a median value of 59.00 mg/dL. Overall, normal laboratory values for Lp(2) (i.e., < 30 mg/dL) were found in 25 patients (4.9%), while abnormal values were detected in 484 patients (95.1%).
Association of independent variables and Lp(a)
Firstly, we confirmed that our study population did not follow a normal distribution, thus, only non-parametric models were applied. As shown in Table 2 The association between Lp(a) and hepatic steatosis with hepatomegaly was also significant (p < 0.001). This analysis compared 208 (40.8%) patients with hepatomegaly (median of 77.90, range: 10.0 -110.0; average: 74.90 ± 18.81) versus 301 (59.1%) patients with steatosis without hepatomegaly (median of 49.00, range: 9.9 -105.0; average 54.05 ± 19.25). Table 3 describes the results that were significant (p < 0.001), regarding the distribution of Lp(a) by age group, with patients older than 50 years, achieving higher median values of Lp(a). Multiple comparisons between age groups (α' = 0.005) allowed to determine that all groups presented significant differences (< 20 years versus other age groups, A positive and significant correlation was found between Lp(a) and the vascular risk scores used in CVD stratification (p < 0.001), as shown in Table 4 . Correlation between Lp(a) and cardiovascular risks was moderate, and high Lp(a) values were associated with high scores of those CV risks stratification tables (i.e., FRS, ASCVD and SCORE).
DISCUSSION
The main finding of this study was that average values of Lp(a) were increased in patients at high vascular risk and were directly correlated with other CVRF. These data constitute valuable information for clinical evaluation, allowing to infer about the adequate orientations and therapeutic interventions, based on the patients' personal and family history. Moreover, this observation can be employed to all three criteria presented for vascular risk calculation, including the SCORE low-risk algorithm, which is applicable to Portuguese patients.
A significant correlation was observed between Lp(a) and IMT, BMI, LDLc, homocysteine, CRP and abdominal circumference, as previously described. 13, 14 The negative, weak significant correlation between Lp(a) and HDLc should also be highlighted. In addition, results regarding height were relevant if considering that the Portuguese population presents an average short height and individuals with pyknic morphology are more susceptible to CVD. Furthermore, the pro-inflammatory effect of Lp(a) is corroborated by its correlation with the CRP. 15 We also highlight the significant relationship between Lp(a) and hepatic steatosis (p < 0.001). Lp(a) values were considerably higher in patients with steatosis. Further studies are required to better understand the relationship in cases of non-alcoholic fatty liver disease (NAFLD) without secondary causes for steatosis, such as excessive alcohol consumption, virus infection or endocrine disorders.
Although results among adult patients are variable, age has been significantly associated with increased Lp(a). 16 Furthermore, besides that Lp(a) values increase with age, a significant difference between younger (20 -39 years) and older (> 60 years) subjects has been described. 17 Therefore, we assessed the effect of age groups on the distribution of Lp(a), which showed that Lp(a) presented a significant association between age groups, except for the two groups of older patients (50 -64 years vs ≥ 65 years; p = 0.540). Thus, an early perception of the vascular risk with an easy and adequate risk stratification in primary prevention should be provided. 18 This information presupposes an early reflection to restructure the intervention procedure, so that patients' mortality and cardiovascular morbidity are reduced. Also, the positive correlation between Lp(a) and vascular risk scores suggest that Lp(a) plays a key role in vascular risk estimation. This correlation should be considered when planning or re-evaluating therapy interventions, in terms of primary prevention. 18 Lp(a) presents some unique features that enable it to enrich the atherosclerotic plaques of cholesterol. Additionally, this lipoprotein has been shown to increase smooth muscle cell migration and proliferation, chemotactic activity, endothelial adhesion molecule expression, foam cell formation and lipid-induced atherogenesis. Lp(a) particles accumulate in human atherosclerotic lesions in the same way as LDLc, but probably more easily, due to their greater affinity to the arterial wall than LDLc. For this reason, increased values of Lp(a) represent a CVRF and should be treated. 19, 20 Similarly to CVD, treatment of NAFLD is focused on reducing CVRF and resistance to insulin. Since well-established therapeutic options are still lacking, lifestyle modifications and treatment of individual risk factors are recommended. 21, 22 Neverthless, albeit the known benefits of diet, followed by physical activity and adequate control of modifiable risk factors, it hasn't been demonstrated that those interventions have an impact on Lp(a) levels. 23 Considering the present results for the Portuguese patients, we can infer that, although the Mediterranean diet is an essential part of primary prevention, 24, 25 it should not be overrated compared to other CVRF that have stronger associations with CVD and related consequences. 26, 27 Therefore, the increased focus on the Mediterranean diet may have contributed to the postponing of more incisive interventions and therapeutic orientations that, if initiated early, could be decisive in reducing the burden of cardiovascular disease. 28, 29 Overall, Lp(a) is associated with conventional CVRF, including high levels of LDLc, and were found to be increased in patients with hepatic steatosis and those with high vascular risk. As such Lp(a) should be valued as a biomarker for an early initiation of therapy and intensive orientations for primary prevention of CVD. 18, 20, 23, 30 Finally, this study presents some limitations inherent to its design and observational nature. For instance, the interpretation of our results should account for possible withinsubject variation and control variables (e.g., BMI, blood pressure and laboratory parameters, such as CRP or Hb Ac1), as well as omitted individuals (missing data), over the study period. Despite these limitations, this study provides us with unique data about the Lp(a) profile in Portuguese patients at high risk of vascular disease, with implications in current clinical practice.
CONCLUSION
In conclusion, Lp(a) is a strong indicator of vascular risk, directly correlated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis. Due to its high availability and low cost, Lp(a) should become part of routine evaluation of at-risk patients in the Portugal.
